Indeed, it is known that when IFN‐α has been used to treat thrombocytosis, chronic hepatitis B and C, and certain types of cancer, NAB are associated with loss of clinical effectiveness [23, 24, 25, 26]. This evidence concerns the gene IFNA1 and thrombocytosis disease.